arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

Agentix Corp.

AGTX
— Price unavailable
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
54 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
49
Health
Weak
Neutral
auto_awesome

Analytical Summary

Agentix Corp. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC 2.6% ↗
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-117.67K
↑ +36.7% —
Operating Margin Operating profit as % of sales
-444.6%
↓ -224.1% —
FCF / Share Free cash flow per share
$-0.00
↑ +96.6% —
Long-Term Debt Long-term obligations
$110.00K
↑ +29.4% —

Health Breakdown

Returns ↓
69
Financial Health ↑
34
Cash Quality ↑
27

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 54 quarters